drugset / Trial / NCT00861185

Study to Assess Safety and Efficacy of Oral Senicapoc Administration on Exercise-induced Asthma

NCT00861185

Phase 2 Completed 69 enrolled Icagen
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether 4 weeks of dosing with senicapoc alleviates exercise induced asthma symptoms.

Timeline

Start
2009-03
Primary completion
2009-07
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Senicapoc Small molecule 40 mg Oral